Investigational Drug Information for Avigan
✉ Email this page to a colleague
What is the development status for investigational drug Avigan?
Avigan is an investigational drug.
There have been 17 clinical trials for Avigan.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 20th 2020.
The most common disease conditions in clinical trials are COVID-19, Hemorrhagic Fever, Ebola, and Lassa Fever. The leading clinical trial sponsors are Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti, and Institut National de la Santé Et de la Recherche Médicale, France.
There are one hundred and thirty-two US patents protecting this investigational drug and one international patent.
Summary for Avigan
| US Patents | 132 |
| International Patents | 1,425 |
| US Patent Applications | 428 |
| WIPO Patent Applications | 474 |
| Japanese Patent Applications | 148 |
| Clinical Trial Progress | Phase 2 (2020-08-20) |
| Vendors | 94 |
Recent Clinical Trials for Avigan
| Title | Sponsor | Phase |
|---|---|---|
| Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever | Alliance for International Medical Action | Phase 2 |
| Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever | Federal Medical Centre, Owo | Phase 2 |
| Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever | Institut National de la Santé Et de la Recherche Médicale, France | Phase 2 |
Clinical Trial Summary for Avigan
Top disease conditions for Avigan
Top clinical trial sponsors for Avigan
US Patents for Avigan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Avigan | See Plans and Pricing | Methods and compositions for inhibition of polymerase | BioCryst Pharmaceuticals, Inc. (Durham, NC) | See Plans and Pricing |
| Avigan | See Plans and Pricing | Methods of preparing inhibitors of influenza viruses replication | Vertex Pharmaceuticals Incorporated (Boston, MA) | See Plans and Pricing |
| Avigan | See Plans and Pricing | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits | ELIAN LLC (Monrovia, CA) | See Plans and Pricing |
| Avigan | See Plans and Pricing | Substituted nucleosides, nucleotides and analogs thereof | Alios BioPharma, Inc. (South San Francisco, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Avigan
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Avigan | Australia | AU2011315902 | 2030-10-15 | See Plans and Pricing |
| Avigan | Australia | AU2017200471 | 2030-10-15 | See Plans and Pricing |
| Avigan | Brazil | BR112013009029 | 2030-10-15 | See Plans and Pricing |
| Avigan | Canada | CA2813783 | 2030-10-15 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
